



Monoclonal Antibodies for Targeted Biological Treatment of Severe Asthma

Guest Editor:

Dr. Corrado Pelaia

Department of Health Sciences,
University “Magna Græcia” of
Catanzaro, Catanzaro, Italy

Deadline for manuscript
submissions:

closed (28 February 2022)

Message from the Guest Editor

Asthma is a chronic respiratory disorder consisting of usually variable bronchial obstruction and hyperresponsiveness. Several endotypes play a crucial role in the pathobiology of asthma, causing heterogeneous clinical manifestations. Within this context, many targets for biological treatment of severe asthma, such as immunoglobulins E (IgE), pro-inflammatory cytokines and their receptors, have been identified. Specifically, omalizumab (anti-IgE), mepolizumab (anti-IL-5), reslizumab (anti-IL-5), benralizumab (anti-IL-5 receptor) and dupilumab (anti-IL-4/IL-3 receptors) are available in clinical practice, providing excellent clinical and functional effects even in a real-life environment. Furthermore, other biologics that target innate cytokines, such as IL-33 and thymic stromal lymphopoietin (TSLP), are under development. The aim is implementing phenotype/endotype-specific treatments, in order to delineate a personalized therapeutic approach tailored on the patient and chosen on the basis of existing and emerging biomarkers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)